Evidence map›Paper›PMID 41125810›Full record

ArticleNpj imaging2025

Confounder-aware foundation modeling for accurate phenotype profiling in cell imaging.

Giorgos Papanastasiou, Pedro P Sanchez, Argyrios Christodoulidis, Guang Yang, Walter Hugo Lopez Pinaya

Abstract read
In one paragraph

Article in Npj imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Single-cell hit calling in high-content imaging screens with Buscar.bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Giorgos Papanastasiou *Artificial Intelligence, Data and Analytics Digital, Pfizer Inc, New York, NY, USA. georgios.papanastasiou@pfizer.com.
Pedro P Sanchez *Sinkove, London, UK.
Argyrios ChristodoulidisResearch and Development Digital, Pfizer Inc, New York, NY, USA.
Guang YangBioengineering Department and Imperial-X, Imperial College London, London, UK. g.yang@imperial.ac.uk.
Walter Hugo Lopez PinayaDepartment of Biomedical Engineering, School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.

Funding

Wellcome Trust
6 · The paper itself

Abstract

Image-based profiling is rapidly transforming drug discovery, offering unprecedented insights into cellular responses. However, experimental variability hinders accurate identification of mechanisms of action (MoA) and compound targets. Existing methods commonly fail to generalize to novel compounds, limiting their utility in exploring uncharted chemical space. To address this, we present a confounder-aware foundation model integrating a causal mechanism within a latent diffusion model, enabling the generation of balanced synthetic datasets for robust biological effect estimation. Trained on over 13 million Cell Painting images and 107 thousand compounds, our model learns robust cellular phenotype representations, mitigating confounder impact. We achieve state-of-the-art MoA and target prediction for both seen (0.66 and 0.65 ROC-AUC) and unseen compounds (0.65 and 0.73 ROC-AUC), significantly surpassing real and batch-corrected data. This innovative framework advances drug discovery by delivering robust biological effect estimations for novel compounds, potentially accelerating hit expansion. Our model establishes a scalable and adaptable foundation for cell imaging, holding the potential to become a cornerstone in data-driven drug discovery.

Identifiers

PMID41125810
PMCPMC12546604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.